- Home
- VOR vs ACRV Comparison
VOR vs ACRV Comparison
Compare VOR & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOR
- ACRV
- Stock Information
- Founded
- VOR 2015
- ACRV 2018
- Country
- VOR United States
- ACRV United States
- Employees
- VOR N/A
- ACRV N/A
- Industry
- VOR Biotechnology: Pharmaceutical Preparations
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- VOR Health Care
- ACRV Health Care
- Exchange
- VOR Nasdaq
- ACRV Nasdaq
- Market Cap
- VOR 134.8M
- ACRV 172.5M
- IPO Year
- VOR 2021
- ACRV 2022
- Fundamental
- Price
- VOR $0.82
- ACRV $5.07
- Analyst Decision
- VOR Strong Buy
- ACRV Strong Buy
- Analyst Count
- VOR 7
- ACRV 6
- Target Price
- VOR $11.36
- ACRV $22.40
- AVG Volume (30 Days)
- VOR 345.1K
- ACRV 37.9K
- Earning Date
- VOR 03-19-2025
- ACRV 03-27-2025
- Dividend Yield
- VOR N/A
- ACRV N/A
- EPS Growth
- VOR N/A
- ACRV N/A
- EPS
- VOR N/A
- ACRV N/A
- Revenue
- VOR N/A
- ACRV N/A
- Revenue This Year
- VOR N/A
- ACRV N/A
- Revenue Next Year
- VOR N/A
- ACRV N/A
- P/E Ratio
- VOR N/A
- ACRV N/A
- Revenue Growth
- VOR N/A
- ACRV N/A
- 52 Week Low
- VOR $0.63
- ACRV $4.69
- 52 Week High
- VOR $2.43
- ACRV $11.90
- Technical
- Relative Strength Index (RSI)
- VOR 28.59
- ACRV 42.18
- Support Level
- VOR $0.85
- ACRV $5.18
- Resistance Level
- VOR $0.93
- ACRV $5.54
- Average True Range (ATR)
- VOR 0.11
- ACRV 0.37
- MACD
- VOR -0.03
- ACRV 0.00
- Stochastic Oscillator
- VOR 0.82
- ACRV 0.00
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.